Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio Closes $1.1M Tranche in Private Placement

NEW YORK (GenomeWeb) – Pressure BioSciences announced today that it has received gross proceeds of $1.1 million from an additional closing on a $5 million private placement.

Added to the July close of a $2.2 million tranche of the offering, the company has raised about $3.3 million thus far. It said that it expects one or more additional closings in "the near future."

Under the terms of the latest closing, Pressure will issue to the participating investors senior secured convertible debentures with a fixed conversion price of $.28 per restricted common share, as well as common stock purchase warrants exercisable into nearly 2 million shares of restricted common stock at an exercise price of $.40 apiece.

Pressure said it netted about $990,000 through the most recent closing, and will use the funds to expand its marketing and sales capabilities, boost its manufacturing and operational capacities, ready itself for a potential up-listing to a regulated stock exchange, and retire all variable rate convertible debt taken prior to the additional equity being raised.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.